Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The role of genetic instability in the pathogenesis of multiple myeloma

Masood Shammas • 28 Sep 2023
IMS 2023
Multiple Myeloma

Masood Shammas, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on how genomics can inform clinicians on how multiple myeloma occurs and how it can be managed. Despite the heterogeneity of genomic aberrations that can result in multiple myeloma, genomics can predict the prognosis in patients, as well as the instability of disease progression. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals